Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 20

    1.

    Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.

    White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW.

    Pharmacoeconomics. 2009;27(9):781-92. doi: 10.2165/11317560-000000000-00000.PMID: 19757871 [PubMed - in process]Related articles

    2.

    Health care utilization and cost burden of herpes zoster in a community population.

    Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P.

    Mayo Clin Proc. 2009 Sep;84(9):787-94.PMID: 19720776 [PubMed - indexed for MEDLINE]Related articles

    3.

    Comparative costs of ertapenem and cefotetan as prophylaxis for elective colorectal surgery.

    Wilson SE, Turpin RS, Kumar RN, Itani KM, Jensen EH, Pellissier JM, Abramson MA.

    Surg Infect (Larchmt). 2008 Jun;9(3):349-56.PMID: 18570576 [PubMed - indexed for MEDLINE]Related articles

    4.

    The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.

    Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.

    Hum Vaccin. 2008 Jan 25;4(3). [Epub ahead of print]PMID: 18382137 [PubMed - as supplied by publisher]Related articles

    5.

    Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia.

    Brisson M, Pellissier JM, Levin MJ.

    Clin Infect Dis. 2007 Dec 1;45(11):1527-9. No abstract available. PMID: 17990240 [PubMed - indexed for MEDLINE]Related articles

    6.

    Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

    Pellissier JM, Brisson M, Levin MJ.

    Vaccine. 2007 Nov 28;25(49):8326-37. Epub 2007 Oct 17.PMID: 17980938 [PubMed - indexed for MEDLINE]Related articles

    7.

    Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

    Insinga RP, Itzler RF, Pellissier JM.

    Pharmacoeconomics. 2007;25(2):155-69.PMID: 17249857 [PubMed - indexed for MEDLINE]Related articles

    8.

    The incidence of herpes zoster in a United States administrative database.

    Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA.

    J Gen Intern Med. 2005 Aug;20(8):748-53.PMID: 16050886 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis.

    Pellissier JM, Watson DJ, Kong SX, Straus WL.

    Ann Intern Med. 2004 May 4;140(9):761; author reply 761-2. No abstract available. PMID: 15126263 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.

    Schnitzer TJ, Kong SX, Mitchell JH, Mavros P, Watson DJ, Pellissier JM, Straus WL.

    Clin Ther. 2003 Dec;25(12):3162-72.PMID: 14749154 [PubMed - indexed for MEDLINE]Related articles

    11.

    An economic overview of prostate carcinoma.

    Ruchlin HS, Pellissier JM.

    Cancer. 2001 Dec 1;92(11):2796-810.PMID: 11753953 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.

    Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA.

    Pharmacoeconomics. 2001;19(10):1039-49.PMID: 11735672 [PubMed - indexed for MEDLINE]Related articles

    13.

    Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.

    Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE.

    Clin Ther. 2001 Jul;23(7):1061-79. Review.PMID: 11519771 [PubMed - indexed for MEDLINE]Related articles

    14.

    Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents.

    Levaux HP, Schonfeld WH, Pellissier JM, Cassidy WM, Sheriff SK, Fitzsimon C.

    Pediatrics. 2001 Aug;108(2):317-25.PMID: 11483794 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs.

    Rahme E, Joseph L, Kong SX, Watson DJ, Pellissier JM, LeLorier J.

    Pharmacoeconomics. 2001;19(5 Pt 2):577-88.PMID: 11465302 [PubMed - indexed for MEDLINE]Related articles

    16.

    The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings.

    Pellissier JM, Coplan PM, Jackson LA, May JE.

    Am J Manag Care. 2000 Sep;6(9):1038-44.PMID: 11184065 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Cost effectiveness of anterior cruciate ligament reconstruction in young adults.

    Gottlob CA, Baker CL Jr, Pellissier JM, Colvin L.

    Clin Orthop Relat Res. 1999 Oct;(367):272-82.PMID: 10546625 [PubMed - indexed for MEDLINE]Related articles

    18.

    Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study.

    Albertsen PC, Pellissier JM, Lowe FC, Girman CJ, Roehrborn CG.

    Clin Ther. 1999 Jun;21(6):1006-24.PMID: 10440624 [PubMed - indexed for MEDLINE]Related articles

    19.

    Introducing patient values into the decision making process for breast cancer screening.

    Pellissier JM, Venta ER.

    Women Health. 1996;24(4):47-67.PMID: 9104764 [PubMed - indexed for MEDLINE]Related articles

    20.

    Continuous-risk utility assessment in medical decision making.

    Hazen GB, Hopp WJ, Pellissier JM.

    Med Decis Making. 1991 Oct-Dec;11(4):294-304.PMID: 1766332 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Find related data

    Search details

    » See more...